comparemela.com

Latest Breaking News On - Marek ciszewski - Page 1 : comparemela.com

FDA Issues Complete Response Letter (CRL) for UDENYCA® ONBODY™ Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-Party Filler; Coherus Also Announces Completion of Toripalimab FDA Inspections

– No issues with clinical efficacy or safety, trial design, labeling, drug substance manufacturing, or device design or manufacturing were identified in the UDENYCA® ONBODY™ CRL – – No.

United statesMarek ciszewskiCoherus biosciencesJodi sieversTheresa lavalleeDevelopment officerDrug administrationShanghai junshi biosciences ltdVp corporate communicationsCoherus biosciences incExchange commissionComplete response letterBiologics license applicationCoherus chief developmentSurface oncologyPrivate securities litigation reform act

Coherus BioSciences Announces New Employment Inducement Grants

REDWOOD CITY, Calif., Sept. 22, 2023 Coherus BioSciences, Inc. , today announced that effective September 20, 2023, the compensation committee of the Company’s board of directors granted.

Marek ciszewskiCoherus biosciences incGlobenewswire incCommencement incentive planNasdaq global select marketBiosciences contact information

Surface Oncology : Coherus Completes Surface Oncology Acquisition - Form 8-K -Today at 09:25 am

Coherus Completes Surface Oncology Acquisition - Clinical-stage product candidates, casdozokitug and CHS-114, significantly advance .

United statesCoheru immunoDenny lanfearMarek ciszewskiJodi sieversCoherus biosciencesCoherus biosciences incGoodwin procterExchange commissionWedbush securities incVp corporate communicationsLatham watkinsArnold porter kaye scholerShanghai junshi biosciences ltdSurface oncology incExchange commission on

Coherus Completes Surface Oncology Acquisition

– Clinical-stage product candidates, casdozokitug and CHS-114, significantly advancenext-generation immuno-oncology portfolio focused on the tumor microenvironment – – I-O combinations will.

United statesMarek ciszewskiDenny lanfearJodi sieversCoheru immunoCoherus biosciencesCoherus biosciences incExchange commissionGoodwin procterSurface oncology incVp corporate communicationsLatham watkinsShanghai junshi biosciences ltdArnold porter kaye scholerWedbush securities incExchange commission on

Coherus BioSciences Announces New Employment Inducement Grants

REDWOOD CITY, Calif., Aug. 22, 2023 Coherus BioSciences, Inc. , today announced that effective August 20, 2023, the compensation committee of the Company’s board of directors granted options.

Marek ciszewskiCoherus biosciences incVice presidentCoherus biosciencesCommencement incentive planNasdaq global select marketBiosciences contact information

vimarsana © 2020. All Rights Reserved.